Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease

Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

NCT02233894 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

NCT02238171 ·Status: COMPLETED

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

NCT02231372 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

NCT02238145 ·Status: COMPLETED

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02173782 ·Status: COMPLETED ·Phase: PHASE3

Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

NCT02233881 ·Status: COMPLETED

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

NCT02236715 ·Status: COMPLETED

Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

NCT02176187 ·Status: TERMINATED ·Phase: PHASE3

Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.

NCT00267917 ·Status: COMPLETED ·Phase: PHASE4

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

NCT02238197 ·Status: COMPLETED

Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis

NCT02233920 ·Status: COMPLETED

Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT02238184 ·Status: COMPLETED

Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02176200 ·Status: TERMINATED ·Phase: PHASE3

Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

NCT02238158 ·Status: COMPLETED

Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00153075 ·Status: COMPLETED ·Phase: PHASE4

Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease

NCT02233907 ·Status: COMPLETED

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

NCT03646864 ·Status: COMPLETED ·Phase: PHASE1

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

NCT04078126 ·Status: COMPLETED ·Phase: PHASE3

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

NCT02442206 ·Status: COMPLETED ·Phase: PHASE4

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02172352 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01204034 ·Status: COMPLETED ·Phase: PHASE3

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278 ·Status: COMPLETED ·Phase: PHASE2

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

NCT02184624 ·Status: COMPLETED ·Phase: PHASE4

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646 ·Status: COMPLETED ·Phase: PHASE3

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00620022 ·Status: COMPLETED ·Phase: PHASE3